Phaseline

Targets › LOXL2

LOXL2 (Lysyl oxidase homolog 2): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Immunology, Respiratory, Oncology; next expected readout Jun 2027.

Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. (UniProt, Q9Y4K0)

Open in Phaseline: the race on LOXL2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbBMS-986278
LOXL2 inhibitor
LOXL2Phase 3Idiopathic Pulmonary Fibrosis; Progressive Pulmonary FibrosisJun 2027
Galecto BiotechGB2064
LOXL2 inhibitor
LOXL2Phase 2Myelofibrosis–

Conditions

Idiopathic Pulmonary Fibrosis (1) Progressive Pulmonary Fibrosis (1) Myelofibrosis (1)

Modalities

small molecule (2)

Companies

Bristol-Myers Squibb (1) Galecto Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.